Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report suggests that tofacitinib may be beneficial for patients with nail disease unresponsive to other treatments.

In this study, topical 5% roxithromycin was effective in restoring hair growth in about half of individuals with androgenetic alopecia without causing adverse effects.

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

In this study, two patients with refractory juvenile dermatomyositis improved clinically and in disease activity after receiving the JAK inhibitor tofacitinib, showing potential effects in managing the condition.

This study suggests that PF-0998425 is an effective androgen receptor antagonist for sebum control and androgenetic alopecia with rapid metabolism reducing the risk of systemic side effects.

Combining finasteride and terazosin can cause severe allergic reactions.

This study found that androgen deprivation therapy is associated with an increased risk of acquired long-QT syndrome and Torsades de Pointes, particularly highlighting enzalutamide's greater association with sudden death compared to other therapies.

This review discusses the use of tofacitinib as a treatment for plaque psoriasis, highlighting its efficacy and safety in clinical trials, but notes unresolved questions regarding long-term safety.

This study found that men receiving enzalutamide and other androgen-deprivation therapies may be at increased risk for QT prolongation and torsades de pointes.

This study found that the hydrophilic PTK-UR foam with EG7 repeats significantly improved wound healing in porcine skin wounds compared to other scaffolds, suggesting potential for synthetic biomaterial applications.

This study found that methotrexate, when administered according to current recommendations, effectively manages rheumatoid arthritis for many patients in Poland, although regular monitoring is necessary due to possible adverse effects.

This study found that ketorolac tert-butyl ester enhances skin permeation and follicular absorption compared to ketorolac, highlighting the role of lipophilicity and solubility in prodrug design.

This case report describes two patients with ulcerative colitis and alopecia areata who did not respond to various treatments but achieved remission and improved hair growth after starting tofacitinib.

Tofacitinib might be used to treat hair loss.

This study concluded that polymeric nanoparticles effectively targeted hair follicles for drug delivery, but the organogel formulation did not enhance their penetration into the hair shaft.

The trial helped find the best dose of deuruxolitinib for treating alopecia areata.

In this case report, a severe case of pediatric alopecia areata was treated with topical ruxolitinib, a Janus kinase inhibitor, highlighting the limited but promising evidence for this treatment in children.

This case report describes a 39-year-old woman whose dermatomyositis-systemic lupus erythematosus overlap syndrome symptoms resolved after switching to tofacitinib.

In this study, researchers developed "Akaro Spectra," an antiparasitic tablet for dogs using cryodestruction of plant materials, which showed 100% efficacy against Otodectes cynotis ticks by the second day and 93.76% efficacy against Ixodes, Dermacentor, and Rhipicephalus ticks.

This study found that a regimen combining cyproterone acetate and testosterone buciclate induced reversible azoospermia in bonnet monkeys, highlighting its potential as an effective male contraceptive.

This systematic review and meta-analysis reported that deuruxolitinib is effective for hair regrowth and improving patient-reported outcomes in individuals with moderate to severe alopecia areata, but observed manageable treatment-emergent adverse events such as elevated creatinine kinase levels and headaches, particularly with higher doses.

This study validated a UV-spectrophotometric method for accurately detecting Minoxidil and Tofacitinib citrate concentrations in bulk and gel formulations for alopecia areata, showing high recovery rates and indicating the method's suitability for routine analysis.

This study found that oral JAK inhibitors, ruxolitinib and tofacitinib, are effective and well-tolerated for treating severe alopecia areata, with a similar degree of hair regrowth and relapse rates, but ruxolitinib induced faster initial hair regrowth.

This article describes an increase in the detection of heart failure among young people and discusses the development of the drug Uperio for its treatment and support.

This review examines nanozymes as promising tools for cancer diagnosis and therapy due to their enzyme-mimicking catalytic properties and highlights their challenges, including biosafety and clinical translation, alongside potential improvements through biomimetic designs, particularly utilizing exosome-based strategies for targeted delivery to tumors.

Deuruxolitinib is generally safe for treating alopecia areata.

This study found that deuruxolitinib may effectively improve hair regrowth and patient satisfaction in moderate to severe alopecia areata, but careful monitoring is needed due to manageable side effects and concerns about long-term safety.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

This review discusses the progress and challenges of targeted protein degradation therapies, highlighting the increasing number of degraders in cancer clinical trials and the limited diversity in targeted proteins, primarily focusing on those employing CRL4^CRBN as the E3 ligase.